NCAN

(redirected from NEUR)
Also found in: Acronyms.

NCAN

A gene on chromosome 19p12 that encodes neurocan, a chondroitin sulphate proteoglycan, which may be involved in modulating neuronal adhesion and migration as well as neurite growth during development, by binding to neural cell adhesion molecules.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
People like Diane Pretty,another motor neur one suff erer,and Danny Boyd, who starved himself to a ``harrowing'' death to escapeabowelcondition.
All paediatric neur osciences services for the North West will be moved to the children 's hospital site.
Graham was the 17th child in the country to undergo a vigorous new treatment for neur oblastoma, which leaves patients with no hair or nails.
Reginald Crew, 74, says he has been robbed of his dignity by motor neur one disease.
)MY KINGDOM, a contemporary film version of King Lear, set in Liverpool, portrays the city as an economicall y-depressed and rav-aged place, centr ed around a gro-tesque and neur otic criminal u nder-world family.
30 December 2010 - Denmark-based biopharma company NeuroSearch A/S (CPH: NEUR) announced today results from a meta-analysis performed on 12 and 26 week datasets from two clinical studies with Huntexil (pridopidine) in the treatment of Huntington's disease: a 26-week Phase III study in 437 patients, the MermaiHD study, and a 12-week Phase IIb study in 227 patients, the HART study.
25 August 2010 - Danish biopharma company Neurosearch A/S (CPH: NEUR) upgraded today its guidance for 2010 after it saw its net loss narrow to DKK63.3m (USD10.8m/EUR8.5m) in the second quarter of 2010 from DKK87.5m a year earlier.
11 March 2010 - Standard & Poor's (S&P) downgraded its share price target but reaffirmed its "strong buy" rating on Danish biopharma company Neurosearch A/S (CPH: NEUR) after the latter posted yesterdayaA its financial results for 2009.
3 February 2010 - Danish biopharma company NeuroSearch A/S (CPH: NEUR) will present later today positive top-line results from a Phase III clinical trial with its drug candidate Huntexil for Huntington's disease, which caused the stock to surge nearly 65% in Copenhagen.